USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
The 20,000 Steps to a Walmart Manager's Six-Figure Salary
Guns and Death Threats in Canada’s Baby-Eel Fisheries
The NBA's Media Rights Are Up for Grabs. Billions Are at Stake.
Mayhem at Paramount as Merger Looms
Trump Allies Draft Plans to Rein in the Fed
Amazon’s Secret Operation to Gather Intel on Rivals
JP Morgan CEO Jamie Dimon on What's Next for the Economy
Pro-Palestinian Protests and Arrests at U.S. Colleges
How Gambling Scandals Are Rocking Sports Leagues
Inside the White House's Scramble to Avert a Bigger Middle East War
Donald Trump’s First Criminal Trial Is Underway
How Cyber Thieves Are Disrupting U.S. Goods
Think It’s Expensive to Buy a Home? Try Owning One.
Why the Fed Is Steering Away From Rate Cuts
Many Cities Fear the ‘Doom Loop.’ St. Louis is in One.
The Russian Military is Using Elon Musk’s Starlink
Can the WNBA Cash in on the Caitlin Clark Effect?
How Employer-Funded Child Care Can Work
What Arizona's Abortion Ban Means for the 2024 Election
Biden’s New Plan to Cancel Student Debt
Create your
podcast in
minutes
It is Free
WSJ Tech News Briefing
WSJ What’s News
WSJ Opinion: Potomac Watch
WSJ Your Money Briefing
The Indicator from Planet Money